Author

Meghan Irwin

Institution: Trillium Therapeutics (Canada)

Observed institution: Trillium Therapeutics (Canada)

OpenAlex ID: A5084355795

A Phase 1 Study of TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

2016 · Stephen Ansell, Robert W Chen, et al. · Blood · 37

A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 Do Not Eat Signal

2017 · Christiane Querfeld, John A. Thompson, et al. · Blood · 17

A phase 1 dose-escalation trial of intratumoral TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides.

2017 · John A. Thompson, Oleg Akilov, et al. · Journal of Clinical Oncology · 8

Intralesional Injection of the CD47-blocking immune checkpoint inhibitor TTI-621 (SIRPaFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and Sézary syndrome: Interim results of a multicenter Phase 1 trial

2018 · Christiane Querfeld, John A. Thompson, et al. · European Journal of Cancer · 7

Effects of TTI-621 (SIRPαFc) on CD47 and serum cytokines associated with phagocytosis in subjects with relapsed, refractory hematologic malignancies: Pharmacodynamic findings from a first-in-human clinical trial.

2017 · Lisa Johnson, Raju K. Pillai, et al. · Journal of Clinical Oncology · 4

Works count: 5

Citation count: 73

H-index: 4

I10-index: 2